Statin Treatment and the Alterations in the Platelet Lipidome: What Is the Impact of Lipid Profile on Thrombosis?
Thrombosis and Haemostasis · 01.06.2023 · 123 (06) · 573-575
DOI: 10.1055/a-2052-9650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.06.2023. Verfasst von Shinichi Goto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine & Family Medicine, Department of General and Acute Medicine, Tokai University School of Medicine, Isehara, Kana…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of General Internal Medicine & Family Medicine, Department of General and Acute Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States.
- Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Kanagawa, Japan.
ORCID-Profile: Shinichi Goto, Shinya Goto
Zitieren
APA
Goto, S., & Goto, S. (2023). Statin Treatment and the Alterations in the Platelet Lipidome: What Is the Impact of Lipid Profile on Thrombosis?. Thrombosis and Haemostasis, 123(06), 573-575. https://doi.org/10.1055/a-2052-9650
Vancouver
Goto S, Goto S. Statin Treatment and the Alterations in the Platelet Lipidome: What Is the Impact of Lipid Profile on Thrombosis?. Thrombosis and Haemostasis. 2023;123(06):573-575. doi:10.1055/a-2052-9650
BibTeX
@article{Goto2023,
author = {Goto, Shinichi and Goto, Shinya},
title = {Statin Treatment and the Alterations in the Platelet Lipidome: What Is the Impact of Lipid Profile on Thrombosis?},
journal = {Thrombosis and Haemostasis},
year = {2023},
volume = {123},
number = {06},
pages = {573--575},
doi = {10.1055/a-2052-9650}
}
EUVIMED